Mathur Tanmay, Bharti Sachidanand Jee, Kumari Lata, Kaushik Shivani, Ratre Brajesh Kumar, Bhatnagar Sushma, Mishra Seema, Gupta Nishkarsh, Garg Rakesh, Kumar Vinod, Khan Maroof Ahmad, Kumar Sunil, Deepak Rakesh Kumar
All India Institute of Medical Sciences, New Delhi, India.
Asian Pac J Cancer Prev. 2024 Dec 1;25(12):4257-4264. doi: 10.31557/APJCP.2024.25.12.4257.
There is a paucity of literature regarding the effect of anesthetic techniques on anti-tumor immunity, especially in Oral cavity Malignancies. We designed a study to evaluate the effect of 3 anesthetic techniques - Opioid, Lignocaine infusion and Dexmeditomedine infusion-based on anti-tumor immunity, using TGF-β, T-helper cell profile and inflammatory markers such as IL-6 and IL-10.
A pilot prospective randomized trial was conducted in 90 patients undergoing surgery for Oral cavity malignancy under general anesthesia in a tertiary specialty cancer hospital. Adult cancer patients of the American Society of Anaesthesiologists (ASA) physical status I-III fulfilling the inclusion criteria were randomized to either group A (Opioid general anesthesia), group B (lignocaine infusion-based general anesthesia), or group C (Dexmedetomidine infusion-based general anesthesia). Preoperative (morning of surgery) and postoperative (24 hours after surgery) blood samples were obtained. Statistical analysis was done, and the results were analyzed.
Demographic profile and pre-operative parameters were comparable between both groups. We did not find any statistically significant difference in the Post-operative levels of TGF-β, neutrophil-lymphocyte ratio (NLR), Monocyte Lymphocyte Ratio (MLR), platelet lymphocyte ratio (PLR), IL-6, IL-10, and T-helper cell profile( IFN-γ, IL-17A, and IL-4 as surrogate markers) among the three study groups. However, it was noted that the overall Opioid consumption was markedly reduced in Group C without any major adverse effects being noted.
关于麻醉技术对抗肿瘤免疫的影响,尤其是在口腔恶性肿瘤方面的文献较少。我们设计了一项研究,以使用转化生长因子-β(TGF-β)、辅助性T细胞谱以及白细胞介素-6(IL-6)和白细胞介素-10等炎症标志物,评估三种麻醉技术——阿片类、利多卡因输注和右美托咪定输注——基于抗肿瘤免疫的效果。
在一家三级专科癌症医院,对90例接受全身麻醉下口腔恶性肿瘤手术的患者进行了一项前瞻性试点随机试验。符合纳入标准的美国麻醉医师协会(ASA)身体状况I-III级的成年癌症患者被随机分为A组(阿片类全身麻醉)、B组(基于利多卡因输注的全身麻醉)或C组(基于右美托咪定输注的全身麻醉)。采集术前(手术当天上午)和术后(手术后24小时)的血样。进行统计分析并分析结果。
两组之间的人口统计学特征和术前参数具有可比性。我们在三个研究组之间未发现术后TGF-β、中性粒细胞与淋巴细胞比值(NLR)、单核细胞与淋巴细胞比值(MLR)、血小板与淋巴细胞比值(PLR)、IL-6、IL-10以及辅助性T细胞谱(以干扰素-γ、白细胞介素-17A和白细胞介素-4作为替代标志物)水平存在任何统计学上的显著差异。然而,值得注意的是,C组的阿片类药物总体消耗量显著降低,且未观察到任何重大不良反应。